Bioheart Announces Commercial Order for TGI 1200(tm) Adult Stem Cell Isolation System for Use in Chronic Limb Ischemia Patients

SUNRISE, Fla., Jan. 14, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT)
announced today it has received a purchase order for a TGI 1200 System from
Philadelphia BioMed Product Development Centre.* 

Bioheart's TGI 1200 System is a fully-automated, point-of-care system that
recovers potentially regenerative cells from a patient's own fat in about an
hour, with minimal operator intervention. No tissue pre-processing is required.
The system, distributed by Bioheart under an exclusive license from Tissue
Genesis, Inc., accepts adipose (fat) tissue from the same device used for
liposuctioning the tissue from the patient. The compact desktop unit readily
fits into any clinical environment and uses preconfigured disposables for quick
and easy assembly. 

The unit will be kept by Philadelphia BioMed at the University of Jordan's Cell
Therapy Centre, under the direction and supervision of Dr. Abdallah Al-Abbadi,
MD, who is Professor of Hematology at the Faculty of Medicine, for use by
vascular surgeons in chronic limb ischemia patients to improve blood
circulation of the limbs and prevent leg amputation. Peripheral vascular
disease commonly affects the arteries supplying the leg and is mostly caused by
atherosclerosis. Further reduction in blood flow causes ischemic pain at rest,
which affects the foot leading to ulceration and gangrene. 

Adipose tissue will be collected from the patient's abdomen and processed in
the TGI 1200 System to collect the adipose stem cells (ASCs). It is believed
that the use of ASCs for treatment of chronic limb ischemia will arrest and
possibly reverse the effects of chronic limb ischemia. 

Bioheart met last month to discuss this project with the research teams at the
University of Jordan, including Dr. Abdelkareem Al-Qudah, the Vice President
for Research and Development at the University of Jordan. 

"The University of Jordan is extremely excited to be a part of this
cutting-edge technology and welcomes advanced clinical studies," said Dr.
Moaath Mousa Al-Samady, MD, a vascular surgeon who will be utilizing the cells
for treating his patients. "We and the cardiovascular surgeons believe that
this will bring new hope to many patients suffering from chronic limb ischemia
as well as diseases related to cardiac dysfunction." 

Bioheart recently completed another pre-clinical study in collaboration with
the University of Jordan under the leadership of Mahmoud Abu-Abeeleh, MD,
assistant professor of Cardiac Surgery, University of Jordan School of
Medicine, utilizing human ASCs to treat myocardial infarction in rats in which
up to 90 percent reduction in myocardial scar size was observed. Bioheart is
expecting to commence human studies for acute myocardial infarction in the near
future. 

*An entity affiliated with a member of Bioheart's Board of Directors 

About Bioheart, Inc.: 

Bioheart, Inc. (Nasdaq:BHRT) is committed to delivering intelligent devices and
biologics that help monitor, diagnose and treat heart failure and
cardiovascular diseases. Its goals are to improve a patient's quality of life
and reduce health care costs and hospitalizations. Specific to biotechnology,
Bioheart is focused on the discovery, development and, subject to regulatory
approval, commercialization of autologous cell therapies for the treatment of
chronic and acute heart damage. Its lead product candidate, MyoCell(r), is an
innovative clinical muscle-derived stem cell therapy designed to populate
regions of scar tissue within a patient's heart with new living cells for the
purpose of improving cardiac function in chronic heart failure patients. The
Company's pipeline includes multiple product candidates for the treatment of
heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose
tissue-derived stem cell treatment for acute heart damage, and MyoCell(r)
SDF-1, a therapy utilizing autologous cells that are genetically modified to
express additional potentially therapeutic growth proteins. For more
information on Bioheart, visit www.bioheartinc.com. 

Forward-Looking Statements: 

Except for historical matters contained herein, statements made in this press
release are forward-looking and are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Without limiting the
generality of the foregoing, words such as "may," "will," "to," "plan,"
"expect," "believe," "anticipate," "intend," "could," "would," "estimate," or
"continue" or the negative other variations thereof or comparable terminology
are intended to identify forward-looking statements. 

Investors and others are cautioned that a variety of factors, including certain
risks, may affect our business and cause actual results to differ materially
from those set forth in the forward-looking statements. These risk factors
include, without limitation, (i) our ability to obtain additional financing;
(ii) our ability to control and reduce our expenses; (iii) our ability to
establish a distribution network for and commence distribution of certain
products for which we have acquired distribution rights; (iv) our ability to
timely and successfully complete our clinical trials; (v) the occurrence of any
unacceptable side effects during or after preclinical and clinical testing of
our product candidates; (vi) the timing of and our ability to obtain and
maintain regulatory approvals for our product candidates; (vii) our dependence
on the success of our lead product candidate; (viii) our inability to predict
the extent of our future losses or if or when we will become profitable; (ix)
our ability to protect our intellectual property rights; and (x) intense
competition. The Company is also subject to the risks and uncertainties
described in its filings with the Securities and Exchange Commission, including
the section entitled "Risk Factors" in its Annual Report on Form 10-K for the
year ended December 31, 2007, as amended by Amendment No. 1 on Form 10-K/A and
its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2008, June
30, 2008 and September 30, 2008. 

CONTACT:  Bioheart, Inc.
          Howard Leonhardt, Chief Executive Officer
          (954) 835-1500
 
          RedChip Companies, Inc.
          Investor Relations:
          Brad Kline
          (800) 733-2447, Ext. 113
          info@redchip.com